« Return to News | R&D Trends

Complete Genomics to provide whole genome sequencing to Mayo Clinic

Friday, February 17, 2012 01:44 PM

Complete Genomics has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing.

The Center for Individualized Medicine determined that collaborating with Complete Genomics could supplement the services available to its community of medical researchers. The center will send genetic material to Complete Genomics for sequencing and analysis, while continuing to operate and invest in its own Medical Genome Facility. Financial details of the agreement were not disclosed.

"It is exciting to see a world-renowned healthcare organization like Mayo Clinic take the next step toward bringing high-quality whole genome sequencing data into the clinic. They clearly recognize its potential to personalize treatment options and improve the future quality of patient care," said Leroy Hood, M.D., Ph.D., member of Complete Genomics' scientific advisory board and president of the Institute for Systems Biology.

Projects will be coordinated with the Center of Individualized Medicine's Medical Genome Facility and will help expedite Mayo Clinic's translational genomics-based programs. Through these initiatives, Mayo Clinic will develop best practices for using genetic information to guide patient care.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.